DeepMed Research

Healthpoint

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1971-01-01

Employees: 501

Market Cap: -

Website: http://www.healthpointchc.org

Clinical Trials

Post Treatment Care After Chemical Peel or Laser Resurfacing

Early Phase 1

Withdrawn

Conditions: Chemical Peel

Interventions: Drug: Aquaphor
Drug: HP828-101

First Posted Date: 2010-06-02

Last Posted Date: 2013-10-01

Lead Sponsor: Healthpoint

Registration Number: NCT01135290

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage

Early Phase 1

Terminated

Conditions: Skin Abnormalities

Interventions: Device: HP828-101

First Posted Date: 2010-04-22

Last Posted Date: 2013-12-06

Lead Sponsor: Healthpoint

Target Recruit Count: 7

Registration Number: NCT01108523

Locations: 🇺🇸
Golden Acres, Dallas, Texas, United States

Santyl vs. Sharp Debridement of Diabetic Foot Wounds

Phase 4

Completed

Conditions: Diabetic Foot Ulcers
Foot Wounds

Interventions: Drug: Santyl
Procedure: Control

First Posted Date: 2010-01-26

Last Posted Date: 2012-11-21

Lead Sponsor: Healthpoint

Target Recruit Count: 48

Registration Number: NCT01056198

Locations: 🇺🇸
St. Elizabeth Regional Medical Center, Lincoln, Nebraska, United States
🇺🇸
UNTHSC Fort Worth, Fort Worth, Texas, United States
🇺🇸
Advanced Regional Center for Ankle and Foot Care, Altoona, Pennsylvania, United States

and more 6 locations

Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds

Not Applicable

Completed

Conditions: Diabetic Foot Ulcers
Pressure Ulcers

Interventions: Device: HP828-101
Device: Hydrogel/Hydrocolloid

First Posted Date: 2009-09-03

Last Posted Date: 2014-01-27

Lead Sponsor: Healthpoint

Target Recruit Count: 88

Registration Number: NCT00971048

Locations: 🇺🇸
Roy Kroeker, Fresno, California, United States
🇺🇸
San Diego Research Center, San Diego, California, United States
🇺🇸
Prigoff-Bowers LLP, Dallas, Texas, United States

and more 8 locations

Safety Follow-Up to HP 802-247-09-015

Completed

Conditions: Venous Leg Ulcer
Venous Stasis Ulcer

Interventions: Biological: No HP802 Treatment
Other: No HP802 Vehicle Treatment

First Posted Date: 2009-05-12

Last Posted Date: 2017-08-02

Lead Sponsor: Healthpoint

Target Recruit Count: 206

Registration Number: NCT00900029

Locations: 🇺🇸
University of AZ College of Medicine, Tucson, Arizona, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
New England Sinai Hospital, Stoughton, Massachusetts, United States

and more 27 locations

Dose Finding Study of HP802-247 in Venous Leg Ulcers

Phase 2

Completed

Conditions: Venous Leg Ulcer
Venous Stasis Ulcers

Interventions: Biological: HP802-247
Biological: Placebo (Vehicle)

First Posted Date: 2009-02-27

Last Posted Date: 2016-10-24

Lead Sponsor: Healthpoint

Target Recruit Count: 228

Registration Number: NCT00852995

Locations: 🇺🇸
Robert J. Snyder, Tamarac, Florida, United States
🇺🇸
New England Sinai Hospital, Stoughton, Massachusetts, United States
🇺🇸
Passavant Area Hospital, Jacksonville, Illinois, United States

and more 27 locations

Contact Sensitization Potential of 828 Ointment

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Device: HP828-101

First Posted Date: 2008-10-07

Last Posted Date: 2014-06-27

Lead Sponsor: Healthpoint

Target Recruit Count: 259

Registration Number: NCT00767676

Locations: 🇺🇸
RCTS, Inc., Irving, Texas, United States

Cumulative Irritation Potential of 828 Ointment

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Device: HP828-101

First Posted Date: 2008-10-07

Last Posted Date: 2014-03-14

Lead Sponsor: Healthpoint

Target Recruit Count: 59

Registration Number: NCT00767455

Locations: 🇺🇸
RCTS, Inc., Irving, Texas, United States

Feasibility Study of the Execution of an Efficacy Trial in the Nursing Home Setting

Phase 2

Withdrawn

Conditions: Partial Thickness Wounds

Interventions: Drug: Xenaderm® Ointment
Drug: Placebo Comparator

First Posted Date: 2008-07-14

Last Posted Date: 2013-08-30

Lead Sponsor: Healthpoint

Registration Number: NCT00714519

Controlled Study of the Effect of Xenaderm® Ointment Vehicle Versus White Petrolatum on Healing

Phase 2

Completed

Conditions: Wounds

Interventions: Drug: Xenaderm Vehicle
Other: Placebo comparator

First Posted Date: 2008-07-11

Last Posted Date: 2013-12-06

Lead Sponsor: Healthpoint

Target Recruit Count: 25

Registration Number: NCT00713349

Locations: 🇺🇸
Dept. of Dermatology, Wake Forrest School of Medicine, Winston-Salem, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy